At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 471–480 of 576 results.
-
Researchers want to find the best dose of abemaciclib to combine with radiation therapy to treat advanced breast cancer. The people in this study have metastatic breast cancer that is fueled by estrogen or progesterone (hormone receptor-positive cancer). In addition, their breast cancer does not make a protein called HER2.
-
The purpose of this study is to find the highest dose of the investigational drug NVL-655 that can be given safely in people with advanced non-small cell lung cancer (NSCLC) or other solid tumors that contain a genetic change called an ALK gene fusion. NVL-655 is a type of drug called a tyrosine kinase inhibitor (TKI), which works by blocking proteins that fuel cancer growth. However, some cancer cells develop resistance to TKI treatment.
-
Researchers want to find the best dose of VLS-1488 to treat various types of advanced cancer. VLS-1488 blocks KIF18A, a protein that plays a role in the rapid growth of cancer cells. By blocking KIF18A, VLS-1488 may cause cancer cells to stop growing and die. VLS-1488 is taken orally (by mouth).
-
The purpose of this study is to find the highest dose of the investigational drug ONO-4685 that can be given safely in people with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL) that came back or continued to grow despite treatment. ONO-4685 may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. It is given intravenously (by vein).
-
Researchers want to find the best dose of 225Ac-ABD147 to treat advanced lung cancer. The people in this study have small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma of the lung (LCNEC). Their cancer keeps growing even after treatment that included platinum-based chemotherapy.
-
Teclistamab is given as an injection under the skin. The goal is to see if lower doses or stopping treatment will have the same benefit with fewer side effects.
-
Hyperthermic intraperitoneal chemotherapy (HIPEC) involves giving heated chemotherapy directly into the belly immediately after surgery to remove an abdominal cancer. Researchers are doing this study to see if HIPEC improves outcomes in people with ovarian cancer. The people in this study have newly diagnosed stage 3 or 4 ovarian cancer.
-
Researchers are seeking the best dose of CABA-201 to treat people with active idiopathic inflammatory myopathy (IIM). The people in this study have IIM, juvenile idiopathic inflammatory myopathy (JIIM), or myositis. With JIIM and some subtypes of IIM, B cells make the body to attack different tissues, causing inflammation and muscle weakness.
-
Researchers in this study are assessing the combination of enfortumab vedotin with pembrolizumab immunotherapy in people with bladder cancer that has spread to nearby lymph nodes and will be surgically removed. Both medications are already used to treat bladder cancer, but their use together before surgery is considered investigational. Both drugs help the immune system attack and kill cancer cells. The study investigators will see if this combination treatment can get rid of cancer in the lymph nodes and shrink patients' tumors before surgery.
-
The purpose of this study is to assess the safety and effectiveness of the investigational immunotherapy LN-145 in patients with non-small cell lung cancer (NSCLC) that has metastasized despite prior treatment. LN-145 is called "autologous tumor infiltrating lymphocytes" (TIL) therapy. It activates white blood cells to attack the tumor.